PURPOSE: To test that prospective delivery of higher thermal dose is associated with longer tumor control duration. EXPERIMENTAL DESIGN: 122 dogs with a heatable soft tissue sarcoma were randomized to receive a low (2-5 CEM43 degrees CT90) or high (20-50 CEM43 degrees CT90) thermal dose in combination with radiotherapy. Most dogs (90%) received four to six hyperthermia treatments over 5 weeks. RESULTS: In the primary analysis, median (95% confidence interval) duration of local control in the low-dose group was 1.2 (0.7-2.1) years versus 1.9 (1.4-3.2) years in the high-dose group (log-rank P = 0.28). The probability (95% confidence interval) of tumor control at 1 year in the low-dose versus high-dose groups was 0.57 (0.43-0.70) versus 0.74 (0.62-0.86), respectively. Using multivariable procedure, thermal dose group (P = 0.023), total duration of heating (P = 0.008), tumor volume (P = 0.041), and tumor grade (P = 0.027) were significantly related to duration of local tumor control. When correcting for volume, grade, and duration of heating, dogs in the low-dose group were 2.3 times as likely to experience local failure. CONCLUSIONS: Thermal dose is directly related to local control duration in irradiated canine sarcomas. Longer heating being associated with shorter local tumor control was unexpected. However, the effect of thermal dose on tumor control was stronger than for heating duration. The heating duration effect is possibly mediated through deleterious effects on tumor oxygenation. These results are the first to show the value of prospectively controlled thermal dose in achieving local tumor control with thermoradiotherapy, and they establish a paradigm for prescribing thermoradiotherapy and writing a thermal prescription.
PURPOSE: To test that prospective delivery of higher thermal dose is associated with longer tumor control duration. EXPERIMENTAL DESIGN: 122 dogs with a heatable soft tissue sarcoma were randomized to receive a low (2-5 CEM43 degrees CT90) or high (20-50 CEM43 degrees CT90) thermal dose in combination with radiotherapy. Most dogs (90%) received four to six hyperthermia treatments over 5 weeks. RESULTS: In the primary analysis, median (95% confidence interval) duration of local control in the low-dose group was 1.2 (0.7-2.1) years versus 1.9 (1.4-3.2) years in the high-dose group (log-rank P = 0.28). The probability (95% confidence interval) of tumor control at 1 year in the low-dose versus high-dose groups was 0.57 (0.43-0.70) versus 0.74 (0.62-0.86), respectively. Using multivariable procedure, thermal dose group (P = 0.023), total duration of heating (P = 0.008), tumor volume (P = 0.041), and tumor grade (P = 0.027) were significantly related to duration of local tumor control. When correcting for volume, grade, and duration of heating, dogs in the low-dose group were 2.3 times as likely to experience local failure. CONCLUSIONS: Thermal dose is directly related to local control duration in irradiated caninesarcomas. Longer heating being associated with shorter local tumor control was unexpected. However, the effect of thermal dose on tumor control was stronger than for heating duration. The heating duration effect is possibly mediated through deleterious effects on tumor oxygenation. These results are the first to show the value of prospectively controlled thermal dose in achieving local tumor control with thermoradiotherapy, and they establish a paradigm for prescribing thermoradiotherapy and writing a thermal prescription.
Authors: Z Vujaskovic; J M Poulson; A A Gaskin; D E Thrall; R L Page; H C Charles; J R MacFall; D M Brizel; R E Meyer; D M Prescott; T V Samulski; M W Dewhirst Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-01 Impact factor: 7.038
Authors: J van der Zee; D González González; G C van Rhoon; J D van Dijk; W L van Putten; A A Hart Journal: Lancet Date: 2000-04-01 Impact factor: 79.321
Authors: K K Fu; T F Pajak; A Trotti; C U Jones; S A Spencer; T L Phillips; A S Garden; J A Ridge; J S Cooper; K K Ang Journal: Int J Radiat Oncol Biol Phys Date: 2000-08-01 Impact factor: 7.038
Authors: D E Thrall; G L Rosner; C Azuma; S M Larue; B C Case; T Samulski; M W Dewhirst Journal: Int J Hyperthermia Date: 2000 Sep-Oct Impact factor: 3.914
Authors: Ellen L Jones; Leonard R Prosnitz; Mark W Dewhirst; P Kelly Marcom; Patricia H Hardenbergh; Lawrence B Marks; David M Brizel; Zeljko Vujaskovic Journal: Clin Cancer Res Date: 2004-07-01 Impact factor: 12.531
Authors: Cory Wyatt; Brian Soher; Paolo Maccarini; H Cecil Charles; Paul Stauffer; James Macfall Journal: Int J Hyperthermia Date: 2009 Impact factor: 3.914
Authors: Donald E Thrall; Paolo Maccarini; Paul Stauffer; James Macfall; Marlene Hauck; Stacey Snyder; Beth Case; Keith Linder; Lan Lan; Linda McCall; Mark W Dewhirst Journal: Int J Hyperthermia Date: 2012 Impact factor: 3.914
Authors: Ari Partanen; Pavel S Yarmolenko; Antti Viitala; Sunil Appanaboyina; Dieter Haemmerich; Ashish Ranjan; Genevieve Jacobs; David Woods; Julia Enholm; Bradford J Wood; Matthew R Dreher Journal: Int J Hyperthermia Date: 2012 Impact factor: 3.914
Authors: Marianne Linthorst; Tomas Drizdal; Hans Joosten; Gerard C van Rhoon; Jacoba van der Zee Journal: Strahlenther Onkol Date: 2011-11-25 Impact factor: 3.621
Authors: Benjamin L Viglianti; Michael Lora-Michiels; Jeanie M Poulson; Lan Lan; Daohai Yu; Dahio Yu; Linda Sanders; Oana Craciunescu; Zeljko Vujaskovic; Donald E Thrall; James Macfall; Cecil H Charles; Terence Wong; Mark W Dewhirst Journal: Clin Cancer Res Date: 2009-07-21 Impact factor: 12.531
Authors: Oana I Craciunescu; Kimberly L Blackwell; Ellen L Jones; James R Macfall; Daohai Yu; Zeljko Vujaskovic; Terence Z Wong; Vlayka Liotcheva; Eric L Rosen; Leonard R Prosnitz; Thaddeus V Samulski; Mark W Dewhirst Journal: Int J Hyperthermia Date: 2009 Impact factor: 3.914